Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

PSMA-targeted radioligand therapy

10 evidence topics · 7 sources

Taxane-naive disease after one ARPI: efficacy versus a change in ARPI
OutcomeLutetium Lu 177 vipivotide tetraxetanChange in ARPIHazard ratio (95% CI)
Radiographic progression-free survival, median months (95% CI)“9.3 (7, NE)”“5.6 (4, 6)”“0.41 (0.29, 0.56)”
Overall survival, median months (95% CI)“24.5 (19.5, 28.9)”“23.1 (19.6, 25.5)”“0.91 (0.72, 1.14)”
Disease after ARPI and taxane chemotherapy: overall survival versus best standard of care
OutcomeLutetium Lu 177 vipivotide tetraxetan plus best standard of careBest standard of careHazard ratio (95% CI)
Overall survival, median months (95% CI)“15.3 (14.2, 16.9)”“11.3 (9.8, 13.5)”“0.62 (0.52, 0.74)”